Of the many COVID-19 vaccines, most countries preferred BioNTech and Sinovac vaccines because of their protection and antibody levels. In studies conducted between the two vaccines, it was revealed that BioNTech was more successful in hospitalization rates. In a study carried out in the past weeks, it was determined that the antibody value increased 162 times in those who had BioNTech and 9 times in those who had Sinovac.
Hacettepe University Faculty of Medicine Head of Department of Pediatric Infectious Diseases Prof. Dr. “Maybe they will have to increase the amount of antibodies in the Biontech/Pfizer vaccine,” Mehmet Ceyhan said in a statement last month. As a result of a study conducted at Stanford University and Emory University, one of the prestigious universities of the USA, it was determined that the immunity of those who received two doses of Pfizer/BioNTech vaccine was over in a short time.
The level of protection decreases 10 times in 7 months:
The scientists examined the blood values they took from 46 healthy young and middle-aged adults, the blood values taken some time after they were vaccinated, and the blood values 6 months after the second dose of the vaccine. As a result of the examinations, it was announced that the antibody level created by the vaccine disappeared within 6 months. Bali Pulendran from Stanford University and Mehul Suthar from Emory University said, “Our research has revealed that the Pfizer/BioNTech vaccine provides very high levels of antibodies against COVID-19. However, this level of protection decreases by about 10 times within 7 months.”
Antibodies to variants such as Delta, Beta and Mu were detected in half of the people examined, while a decrease was announced after the sixth month. “These results reveal that 6 to 7 months after the second dose of vaccine, the third dose of the booster coronavirus vaccine will strengthen the protection against SARS-CoV-2 and its variants,” said the scientists who conducted the study.
49255
